
Page#1
AMGEN INC.
CONSOLIDATED STATEMENTS OF INCOME
Years ended December 31, 2019, 2018 and 2017
(In millions, except per-share data)
 
2019 2018 2017
Revenues: 
Product sales $ 22,204  $ 22,533  $ 21,795
Other revenues 1,158  1,214  1,054
Total revenues 23,362  23,747  22,849
 
Operating expenses: 
Cost of sales 4,356  4,101  4,069
Research and development 4,116  3,737  3,562
Selling, general and administrative 5,150  5,332  4,870
Other 66  314  375
Total operating expenses 13,688  13,484  12,876
 
Operating income 9,674  10,263  9,973
 
Interest expense, net 1,289  1,392  1,304
Interest and other income, net 753  674  928
 
Income before income taxes 9,138  9,545  9,597
 
Provision for income taxes 1,296  1,151  7,618
 
Net income $ 7,842  $ 8,394  $ 1,979
 
Earnings per share: 
Basic $ 12.96  $ 12.70  $ 2.71
Diluted $ 12.88  $ 12.62  $ 2.69
 
Shares used in the calculation of earnings per share: 
Basic 605  661  731
Diluted 609  665  735
See accompanying notes.
F-4
Page#2
AMGEN INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
Years ended December 31, 2019, 2018 and 2017
(In millions)
 
2019 2018 2017
Net income $ 7,842  $ 8,394  $ 1,979
Other comprehensive income (loss), net of reclassification adjustments and taxes:  
(Losses) gains on foreign currency translation (48)  (141)  81
(Losses) gains on cash flow hedges (66)  247  (288)
Gains (losses) on available-for-sale securities 360  (185)  (6)
Other (losses) gains (5)  (2)  5
Other comprehensive income (loss), net of taxes 241  (81)  (208)
Comprehensive income $ 8,083  $ 8,313  $ 1,771
See accompanying notes.
F-5
Page#3
AMGEN INC.
CONSOLIDATED BALANCE SHEETS
December 31, 2019 and 2018
(In millions, except per-share data)
  
2019 2018
ASSETS
Current assets: 
Cash and cash equivalents $ 6,037  $ 6,945
Marketable securities 2,874  22,359
Trade receivables, net 4,057  3,580
Inventories 3,584  2,940
Other current assets 1,888  1,794
Total current assets 18,440  37,618
 
Property, plant and equipment, net 4,928  4,958
Intangible assets, net 19,413  7,443
Goodwill 14,703  14,699
Other assets 2,223  1,698
Total assets $ 59,707  $ 66,416
 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities: 
Accounts payable $ 1,371  $ 1,207
Accrued liabilities 8,511  7,862
Current portion of long-term debt 2,953  4,419
Total current liabilities 12,835  13,488
 
Long-term debt 26,950  29,510
Long-term deferred tax liabilities 606  864
Long-term tax liabilities 8,037  8,770
Other noncurrent liabilities 1,606  1,284
 
Contingencies and commitments 
 
Stockholders’ equity: 
Common stock and additional paid-in capital; $0.0001 par value per share; 2,750.0 shares authorized;
outstanding—591.4 shares in 2019 and 629.6 shares in 2018 31,531  31,246
Accumulated deficit (21,330)  (17,977)
Accumulated other comprehensive loss (528)  (769)
Total stockholders’ equity 9,673  12,500
Total liabilities and stockholders’ equity $ 59,707  $ 66,416
See accompanying notes.
F-6
Page#4
AMGEN INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
Years ended December 31, 2019, 2018 and 2017
(In millions)
 
2019 2018 2017
Cash flows from operating activities: 
Net income $ 7,842  $ 8,394  $ 1,979
Depreciation, amortization and other 2,206  1,946  1,955
Stock-based compensation expense 308  311  329
Deferred income taxes (289)  (363)  (1,330)
Other items, net (186)  386  334
Changes in operating assets and liabilities, net of acquisitions: 
Trade receivables, net (504)  (378)  (58)
Inventories (66)  (3)  133
Other assets 10  35  (24)
Accounts payable 164  (143)  424
Accrued income taxes, net (585)  (361)  523
Long-term tax liabilities (146)  258  6,681
Other liabilities 396  1,214  231
Net cash provided by operating activities 9,150  11,296  11,177
Cash flows from investing activities: 
Purchases of marketable securities (9,394)  (18,741)  (33,607)
Proceeds from sales of marketable securities 8,842  28,356  24,240
Proceeds from maturities of marketable securities 20,548  5,412  6,174
Purchases of property, plant and equipment (618)  (738)  (664)
Cash paid for acquisitions, net of cash acquired (13,617)  195  (19)
Other (52)  (145)  (148)
Net cash provided by (used in) investing activities 5,709  14,339  (4,024)
Cash flows from financing activities: 
Net proceeds from issuance of debt —  —  4,476
Repayment of debt (4,514)  (1,121)  (4,405)
Repurchases of common stock (7,702)  (17,794)  (3,160)
Dividends paid (3,509)  (3,507)  (3,365)
Withholding taxes arising from shares withheld for share-based payments (137)  (126)  (191)
Other 95  58  51
Net cash used in financing activities (15,767)  (22,490)  (6,594)
(Decrease) increase in cash and cash equivalents (908)  3,145  559
Cash and cash equivalents at beginning of year 6,945  3,800  3,241
Cash and cash equivalents at end of year $ 6,037  $ 6,945  $ 3,800
See accompanying notes.
F-8